Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

  1. Agache, I.
  2. Rocha, C.
  3. Beltran, J.
  4. Song, Y.
  5. Posso, M.
  6. Solà, I.
  7. Alonso-Coello, P.
  8. Akdis, C.
  9. Akdis, M.
  10. Canonica, G.W.
  11. Casale, T.
  12. Chivato, T.
  13. Corren, J.
  14. Del Giacco, S.
  15. Eiwegger, T.
  16. Firinu, D.
  17. Gern, J.E.
  18. Hamelmann, E.
  19. Hanania, N.
  20. Mäkelä, M.
  21. Martín, I.H.
  22. Nair, P.
  23. O'Mahony, L.
  24. Papadopoulos, N.G.
  25. Papi, A.
  26. Park, H.-S.
  27. Pérez de Llano, L.
  28. Quirce, S.
  29. Sastre, J.
  30. Shamji, M.
  31. Schwarze, J.
  32. Canelo-Aybar, C.
  33. Palomares, O.
  34. Jutel, M.
  35. Montrer des auteurs +
Revue:
Allergy: European Journal of Allergy and Clinical Immunology

ISSN: 1398-9995,  0105-4538

Année de publication: 2020

Volumen: 75

Número: 5

Pages: 1043-1057

Type: Article

DOI: 10.1111/ALL.14235 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus